| Expression pattern: |
UP |
| Associated gene: |
LINC00632 |
| Associated microRNA: |
miRNA-7 |
| Biological function: |
Associated with clinical response/resistance to anti-PD-1 immune checkpoint blockade (nivolumab); proposed biomarker of response. |
| Molecular mechanism: |
Putative ceRNA/miRNA sponge mechanism (sponging miRNA-7) in the context of ICB response. |
| Biological pathway or process: |
ceRNA regulation (other); immune regulation (other) |
| Detected method: |
Q
S
|
| Validation methods: |
RNA-seq; RT-qPCR; Clinical Sample Validation; Bioinformatics Analysis |
| Clinical significance: |
Potential biomarker of response to nivolumab in metastatic cutaneous melanoma. |
| Description: |
CDR1-AS (hsa-CDR1_0001) is differentially expressed between nivolumab responders and non-responders in cutaneous metastatic melanoma and is highlighted as a potential biomarker of ICB response. The study supports a putative ceRNA role for this circRNA, consistent with miRNA sponge activity (including miRNA-7, per prior knowledge), within immune-response regulatory networks. |
| Confidence score: |
0.4032 |